The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial. (Q48665540)
Jump to navigation
Jump to search
scientific article published on 8 June 2012
Language | Label | Description | Also known as |
---|---|---|---|
English | The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial. |
scientific article published on 8 June 2012 |
Statements
1 reference
The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial. (English)
1 reference
Abraham Weizman
1 reference
Tamar Green
1 reference
Lital Steingart
1 reference
Amos Frisch
1 reference
Omer Zarchi
1 reference
Doron Gothelf
1 reference
8 June 2012
1 reference
1 reference
119
1 reference
11
1 reference
1417-1423
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference